Dr. Goldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
VCU Department of Neurology
Richmond, VA 23298Phone+1 804-827-1504
Education & Training
Rush University Medical CenterInternship, Internal Medicine, 1999 - 2000
Rush Medical College of Rush University Medical CenterClass of 1999
Certifications & Licensure
VA State Medical License 2000 - 2026
OH State Medical License 2003 - 2007
IL State Medical License 1999 - 2000- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Clinical Trials
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Clinical Importance of Glucose Regulation in Relapsing MS Start of enrollment: 2016 Oct 01
Publications & Presentations
PubMed
- 58 citationsSafety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.Bruce A.C. Cree, Gary Cutter, Jerry S. Wolinsky, M. S. Freedman, Giancarlo Comi
The Lancet. Neurology. 2020-12-01 - 107 citationsPossible clinical outcome measures for clinical trials in patients with multiple sclerosis.Myla D. Goldman, Robert W. Motl, Richard A. Rudick
Therapeutic Advances in Neurological Disorders. 2010-07-01 - 217 citationsValidity of performance scales for disability assessment in multiple sclerosisRuth Ann M Marrie, Myla D. Goldman
Multiple Sclerosis. 2007-07-10
Journal Articles
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisMyla D Goldman, Amit Bar-Or, JAMA Neurology
Authored Content
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisAugust 2020
Press Mentions
The Multiple Sclerosis Clinic(s) and Research at UVAApril 4th, 2018
Multiple Sclerosis: Smoking After Diagnosis Linked to Disease ProgressionSeptember 9th, 2015
Quitting Smoking After MS Diagnosis May Delay Disease ProgressionSeptember 8th, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
